Reuters logo
BRIEF-Ocular Therapeutix announced positive results of patient experience study of Dextenza
March 15, 2017 / 2:29 PM / 8 months ago

BRIEF-Ocular Therapeutix announced positive results of patient experience study of Dextenza

March 15 (Reuters) - Ocular Therapeutix Inc

* Ocular Therapeutix Inc - announced positive results of patient experience study of dextenza (dexamethasone insert) 0.4 mg for intracanalicular use

* Nda for dextenza is currently under review by fda for treatment of ocular pain occurring after ophthalmic surgery

* Fda has set a pdufa target action date for july 19, 2017

* Ocular therapeutix - intends to submit an nda supplement for dextenza to broaden its label to include a post-surgical inflammation indication

* All patients reported that intracanalicular insert was comfortable Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below